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The mechanisms involved in the transport of the CFTR protein remain almost un-
known. Here, we examined IB3−1 (bronchial cells from patients with dF508CFTR)
and S9 (IB3−1 cells stably transfected with wt CFTR) cells have been examined. We
showed that wtCFTR did not co-localized with giantin, although some patches of
wtCFTR were localized near the Golgi region (but never co-localizing with giantin
or ManII), some were integrated into the PM. In contrast, dF508CFTR remained
mostly in the ER. In IB3−1 and S9 cells, dF508CFTR was mostly localized in the
ER, close to the nucleus (perinuclear region), and wtCFTR was scattered all over the
cell, forming vacuoles. To visualize CFTR at the apical PM, we incubated conﬂuent
monolayers of IB3−1 and S9 cells on ice with the antibody. After washout and
labelling with a secondary antibody, the signal from IB3−1 cells was signiﬁcantly
different from that of S9 cells, suggesting that, indeed, in IB3−1 cells dF508CFTR
is not seen at the PM. Careful electron microscopic examination of IB3−1 and
S9 cells revealed striking differences between the structures of the Golgi in these
cells. In IB3−1 cells, the Golgi was normal, with the usual compartments; in S9
cells stably transfected with wtCFTR, there was hypertrophy of the intermediate
compartment and appearance of the characteristic reticular subdomain within it. In
some cases, this subdomain was within the forming autophagosomes. These data
suggest that CFTR uses an unusual transport pathway.
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Lack of inhibition of amiloride sensitive Na+ channel (ENaC) by defective CFTR
in cystic ﬁbrosis (CF) is regarded as an important reason for the enhanced epithelial
Na+ conductance in the airway and intestinal epithelia of CF patients. Thus, the
regulatory interactions of CFTR and ENaC are likely to inﬂuence the CF phenotype.
Among the many intestinal epithelial cell lines that have been characterized, the
T84 cell line has gained wide acceptance as a general model of transepithelial
anion transport, because their short circuit current (Isc) is wholly representative
of Cl− secretion. Interestingly, we found that when T84 cells were grown in the
presence of 5 mM butyrate for up to 72 h, a gradual appearance of ENaC activity
was observed that reached a plateau after 24 h. The appearance of ENaC activity
correlated with an inhibition of the CFTR-mediated Cl− secretion. Quantitative RT-
PCR analysis of ENaC subunit expression indicated that butyrate stimulated a and g
but had no effect on b subunits. Similar analysis indicated that butyrate had no
effect on the expression of CFTR mRNA. The qRT-PCR results were conﬁrmed
by Western blot studies. Trichostatin A, a speciﬁc inhibitor of histone deacetylase,
mimicked the effects of butyrate, suggesting that butyrate affects ENaC expression
by inhibiting deacetylases. The Isc measurements in basolaterally- or apically-
permeabilized T84 cells indicated that the main effect of butyrate was activation of
ENaC and inhibition of CFTR Cl− channels in the apical membrane. We conclude
that butyrate plays a crucial role in regulating colonic Na+ absorption. Since
both ENaC and CFTR are highly expressed in T84 cells cultured in the presence
of butyrate, T84 cells may provide an important model to study CFTR−ENaC
interactions in intestinal epithelia.
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Cystic ﬁbrosis (CF) is caused by a mutation in the cystic ﬁbrosis transmembrane
conductance regulator (CFTR) gene. In CF, the most common mutant DF508-CFTR
is misfolded and is retained in the ER where it is rapidly degraded. Nevertheless,
if conditions could allow the DF508-CFTR to reach and to stabilize in the plasma
membrane, it could partially correct the CF defect. We have previously shown
that annexin V (anxA5) binds to both the normal CFTR and the DF508-CFTR
in a Ca2+-dependent manner and that it regulates the chloride channel function
of Wt-CFTR through its membrane integration. Our aim was to extend this latest
ﬁnding to the DF508-CFTR. Using co-immunoprecipitation we ﬁrst show that the
DF508 mutation does not disrupt the anxA5-CFTR interaction. Using a siRNA
and the cDNA encoding anxA5, we modulated the anxA5 expression in DF508-
CFTR expressing cells. The chloride channel function of the mutated CFTR was
further assessed by SPQ and patch-clamp experiments. Our results show that
the increased anxA5 expression induces an increased function of DF508-CFTR
and that the reduced anxA5 expression is followed by a decreased DF508-CFTR
function. Using immunoﬂuorescence and membrane protein biotinylation, we show
that the observed increased chloride channel function is due to an increased
membrane localization of DF508-CFTR. Therefore, we suggest that anxA5 which
is endogenously expressed in the lung cells, is a potential therapeutic target in CF.
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Cystic ﬁbrosis (CF) is a fatal disease affecting the lungs and digestive system by
impairment of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
Many aspects of both WT and mutant CFTR regulation, maturation, trafﬁcking and
degradation remain unclear until today. The most common mutation found in CF
patients (DF508) results in the synthesis of a CFTR protein that is unable to fold
properly and assume its appropriate tertiary conformation.
The SUMO protein is covalently conjugated to a lysine residue embedded in a
speciﬁc target motif Y-K-X-E regulating a large number of mostly nuclear proteins.
Recently, evidence has mounted that SUMOylation also plays a role in the regulation
of membrane proteins.
We have identiﬁed 2 highly conserved SUMO binding sites in the CFTR protein
and were able to demonstrate SUMOylation events both in vivo and vitro using
yeast two-hybrid tests and co-immunoprecipiation analysis. Additional support for
our ﬁndings is provided by experiments demonstrating that the SUMO conjugation
enzyme UBC9 binds to WT and DF508 CFTR.
Elimination of the SUMO sites by site-directed mutagenesis results in a substantial
decrease of fully glycosylated WT CFTR on one hand and a signiﬁcant increase of
DF508 CFTR abundance on the other hand. Cell surface biotinylation experiments
conﬁrmed these ﬁndings and mutations of both SUMO motifs in WT CFTR
inhibited its membrane transport. Gradient centrifugation experiments revealed that
WT CFTR with SUMO motif mutations can escape the ER but is unable to leave
the Golgi apparatus.
In summary, we present an entirely new mechanism for the regulation of CFTR
maturation and membrane trafﬁcking.
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